Science & technology · Pipeline & development
Lipid nanoparticle-delivered Cas13b ribonucleoproteins targeting survivin overcome gemcitabine resistance in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely due to its poor response to chemotherapy and the development of drug resistance. Survivin (BIRC5), an inhibitor of apoptosis frequently overexpressed in PDAC, contributes to tumor cell survival and gemcitabine resistance, making it an attractive therapeutic target. Here, we developed a lipid nanoparticle (LNP)-ba
Original source
Read the source — biorxiv.org ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.